CN105213991A - Be used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease - Google Patents
Be used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease Download PDFInfo
- Publication number
- CN105213991A CN105213991A CN201510726779.XA CN201510726779A CN105213991A CN 105213991 A CN105213991 A CN 105213991A CN 201510726779 A CN201510726779 A CN 201510726779A CN 105213991 A CN105213991 A CN 105213991A
- Authority
- CN
- China
- Prior art keywords
- radix
- concha
- treatment
- rhizoma
- gastroesophageal reflux
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to pharmaceutical formulation field, specifically a kind of Chinese medicine composition being used for the treatment of gastroesophageal reflux disease, it is characterized in that being made up of the crude drug of following weight portion: Radix Bupleuri 5 ~ 9, the Radix Paeoniae Alba 4 ~ 7, Fructus Aurantii 4 ~ 8, Fructus Toosendan 4 ~ 7, Rhizoma Corydalis 4 ~ 8, Rhizoma Coptidis 5 ~ 8, Fructus Evodiae 6 ~ 9, Radix Curcumae 6 ~ 9, Endothelium Corneum Gigeriae Galli 7 ~ 9, Radix Clematidis 6 ~ 9, Radix Notoginseng 2 ~ 5, Pseudobulbus Bletillae (Rhizoma Bletillae) 6 ~ 9, Os Sepiae 2 ~ 5, Bulbus Fritillariae Thunbergii 4 ~ 6, Concha Arcae 2 ~ 4, Concha Ostreae 4 ~ 6, Radix Glycyrrhizae Preparata 2 ~ 4, Concha Margaritifera 7 ~ 9, by medicinal for above-mentioned raw materials water soaking, filtrate of removing slag after decocting to obtain.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine preparation, specifically a kind of Chinese medicine composition being used for the treatment of gastroesophageal reflux disease.
Background technology
As everyone knows, gastroesophageal reflux disease refers to that gastroduodenal content reflux enters esophagus and causes the symptoms such as heartburn, can cause reflux esophagitis, and the histologic lesion that the esophagus such as throat, trachea closes on.Gastroesophageal reflux disease male more than women, gastroesophageal reflux disease in Beijing, the prevalence of two places, Shanghai is 5.77%.Heartburn and reflux is the modal symptom of primary disease, in addition also can occur the discomfort such as chest pain, dysphagia, cough.Chinese medicine there is no the record of gastroesophageal reflux disease, but roughly primary disease can be attributed to " acid regurgitation " sick category according to its clinical manifestation.Its pathogenesis is incoordination between the liver and stomach at all, stomach-QI being unable to descend normally, gastric qi and gastric juice superinverse and send out as primary disease.
Current Drug therapy is mainly and controls symptom, improves the state of an illness, gastric acid secretion inhibiting and protection gastric mucosa etc.; based on acid suppression, protection gastric mucosa; clinically based on proton pump inhibitor; this type of medicine can amelioration of inflammation alleviate the discomforts such as heartburn, pantothenic acid; but easily recurrent exerbation; this type of medicine of prolonged application is large and side effect is many to actual bodily harm.
Summary of the invention
Object of the present invention is exactly to overcome above-mentioned existing technical deficiency, provides a kind of evident in efficacy, with low cost, Chinese medicine being used for the treatment of gastroesophageal reflux disease of having no side effect.
The technical scheme that the present invention solves the problems of the technologies described above employing is: a kind of Chinese medicine composition being used for the treatment of gastroesophageal reflux disease, it is characterized in that being made up of the crude drug of following weight portion: Radix Bupleuri 5 ~ 9, the Radix Paeoniae Alba 4 ~ 7, Fructus Aurantii 4 ~ 8, Fructus Toosendan 4 ~ 7, Rhizoma Corydalis 4 ~ 8, Rhizoma Coptidis 5 ~ 8, Fructus Evodiae 6 ~ 9, Radix Curcumae 6 ~ 9, Endothelium Corneum Gigeriae Galli 7 ~ 9, Radix Clematidis 6 ~ 9, Radix Notoginseng 2 ~ 5, Pseudobulbus Bletillae (Rhizoma Bletillae) 6 ~ 9, Os Sepiae 2 ~ 5, Bulbus Fritillariae Thunbergii 4 ~ 6, Concha Arcae 2 ~ 4, Concha Ostreae 4 ~ 6, Radix Glycyrrhizae Preparata 2 ~ 4, Concha Margaritifera 7 ~ 9, by medicinal for above-mentioned raw materials water soaking, to remove slag after decocting to obtain filtrate.
The invention has the beneficial effects as follows, evident in efficacy, with low cost, have no side effect.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described:
Embodiment 1:
Radix Bupleuri, the Radix Paeoniae Alba, Fructus Aurantii, Fructus Toosendan, Rhizoma Corydalis, Rhizoma Coptidis, Fructus Evodiae, Radix Curcumae, Endothelium Corneum Gigeriae Galli, Radix Clematidis, Radix Notoginseng, Pseudobulbus Bletillae (Rhizoma Bletillae), Os Sepiae, Bulbus Fritillariae Thunbergii, Concha Arcae, Concha Ostreae, Radix Glycyrrhizae Preparata, Concha Margaritifera is adopted to be that raw material is prepared from.The every pair of its component (weight) is Radix Bupleuri 7, the Radix Paeoniae Alba 6, Fructus Aurantii 6, Fructus Toosendan 5, Rhizoma Corydalis 6, Rhizoma Coptidis 6, Fructus Evodiae 7, Radix Curcumae 7, Endothelium Corneum Gigeriae Galli 8, Radix Clematidis 7, Radix Notoginseng 4, Pseudobulbus Bletillae (Rhizoma Bletillae) 8, Os Sepiae 3, Bulbus Fritillariae Thunbergii 5, Concha Arcae 3, Concha Ostreae 5, Radix Glycyrrhizae Preparata 3, Concha Margaritifera 8.Get above-mentioned 18 taste raw materials, gross weight is 176 grams, add water 800 ~ 900 milliliters and at room temperature soak 5 ~ 6 hours, slow fire decocted to 60 ~ 80 minutes, filtrate about 150 milliliters of removing slag to obtain, and medicinal residues add water 200 ~ 300ml again, decoct 20 ~ 30 minutes, to remove slag to obtain filtrate 50 ~ 70 milliliters, altogether the medicine juice of about 200 ~ 220 milliliters, i.e. obtained decoction of the present invention.Load in sterile glass vials, seal bottle cap is for subsequent use, and every day 1 dose point 2 times is oral, sooner or later respectively once, and each (medicine) being taken before meal 100 ~ 110 milliliters.
Radix Bupleuri function of the present invention induce sweat bring down a fever, dispersing the stagnated live-QI to relieve the stagnation of QI, ascending up spleen-Qi and Yang, the pungent row hardship of this product is let out, and property is apt to bar and is reached irritability, dispersing the stagnated live-QI to relieve the stagnation of QI, treatment the liver failing to maintain the normal flow of QI, and the pantothenic acid caused by mechanism of qi retardance hits pathogenesis, respond well; Radix Paeoniae Alba function nourishes blood yin fluid astringing, comb pain, suppressing liver-YANG, and liver-yin is held back in this product acid, nourishing blood to suppress the hyperactive liver pain relieving, clinical normal and Radix Bupleuri is compatible; Fructus Aurantii function dispelling the stagnated QI removing food stagnancy, reduce phlegm except painful abdominal mass, for depression of liver-QI, the pantothenic acid of incoordination between the liver and stomach is respond well; Fructus Toosendan, Rhizoma Corydalis match for Sichuan Chinaberry Powder, function dispersing the stagnated live-QI to relieve the stagnation of QI, circulation of qi promoting of stimulating the menstrual flow, the pathogenesis of incoordination between the liver and stomach of hitting; Rhizoma Coptidis, Fructus Evodiae match for Zuojin Wan, are the specially side of Chinese traditional treatment pantothenic acid, the pantothenic acid caused for incoordination between the liver and stomach, heartburnly have special effect; It is that two gold medals fall apart that Radix Curcumae, Endothelium Corneum Gigeriae Galli match, the two dispersing liver-energy, and a line gastric qi, plays the merit of dispersing the stagnated liver-QI for regulating the stomach altogether; Radix Clematidis can pass through 12 warps, for each all effective through the stagnation of QI; Radix Notoginseng, both Pseudobulbus Bletillae (Rhizoma Bletillae) match function hemostasis, granulation promoting, detumescence, pain relieving, and for incoordination between the liver and stomach, in blood network, the wounded is effective; Os Sepiae, Bulbus Fritillariae Thunbergii, Concha Arcae, oyster pearl these four medicines female all can antacid, pain relieving, be the product that clinical treatment is heartburn, pantothenic acid must be used; Radix Glycyrrhizae Preparata coordinating the actions of various ingredients in a prescription.
The each raw material of the present invention also can the embodiment that mixes of ratio (weight portion) listed by according to the form below realize.Its processing technique is identical with embodiment 1.
The clinical trial carried out below in conjunction with my institute is done further the present invention, is described in detail:
1, physical data
In 100 routine patients, in age 25-71 year, the course of disease is many at 3 months to 10 years, 62 years old mean age.
2, diagnostic criteria
With reference to China's gastroesophageal reflux disease National Consensus expert group of disease for digest branch of Chinese Medical Association " Chinese gastroesophageal reflux disease National Consensus " (2006, Sanya).
(1) clinical symptoms
When acid regurgitation, heartburn, retrosternal pain or the classical symptom such as discomfort, belch appear comprising in patient, or when there is the outer symptom of the esophagus such as throat discomfort, cough, gastroesophageal reflux disease can be thought of as simultaneously.If alleged occurrence Esophageal Mucosa inflammation and/or reflux, then can clarify a diagnosis.
(2) endoscopy
Endoscopy can clearly with or without reflux esophagitis (RE) and Barrett esophagus (BE).
The LA classification method of the classification reference Los Angeles,U.S world gastrointestinal disease conference formulation in 1994 of RE.
A level: Esophageal Mucosa has one or several mucosa damaged, and diameter is less than 5mm;
B level: one or several mucosa is damaged, and diameter is greater than 5mm, but amixis phenomenon between breakage;
C level: more than mucosa amalgamation damages more than 2 pleats, but be less than the esophagus Zhou Jing of 75%;
D level: the esophagus Zhou Jing of mucosa damaged range of fusion mutually accumulation at least 75%.
The diagnosis of BE, mainly according to endoscopy and Esophageal Mucosa biopsy, when endoscopy finds that distal esophagus has obvious Columnar epithelium metaplasia and obtains pathological examination confirmation, can be diagnosed as BE.
3, Therapeutic Method
Take embodiment decoction, every day 1 dose point 2 times is oral, sooner or later each once, each (medicine) being taken before meal 100 ~ 110 milliliters 10 days was 1 course for the treatment of.
4, therapeutic outcome:
4.1 treatment evaluation criterias, with reference to 2009 the spleen-stomach disease branch of China Association of Traditional Chinese Medicine " Gastroesphageal Reflux Disease Treated by Chinese Medicine National Consensus " evaluate.
Recovery from illness: transference cure.
Effective: symptom improves percentage rate >=80%.
Progressive: 50%≤symptom improves percentage rate < 80%.
Invalid: symptom improves percentage rate < 50%.
Worsen: symptom improves percentage rate negative value.
Recovery from illness and effective case load calculate total effective rate.
4.2 results: in 100 routine patients, clinical cure 56 example (56.00%), effective 32 examples (32.00%), progressive 12 examples (12.00%), worsen 0 example (0%), total effective rate is 88.00%.
Model case
1, week certain, man, 39 years old, heartburn, pantothenic acid more than 3 years, patient was heartburn over nearly 3 years, pantothenic acid recurrent exerbation, once repeatedly row electronic gastroscopy prompting gastroesophageal reflux disease, repeatedly oral proton pump inhibitor, and when taking medicine, symptom can be alleviated, and recurs after drug withdrawal.Very, companion's belch does not relax existing heartburn, the pantothenic acid of patient, and sense epigastrium distension is uncomfortable, bitter taste, mouth odor.Check: abdomen is soft, and abdominal part is without tenderness and rebound tenderness, and Liver and kidney district is without percussion pain.Diagnosis: gastroesophageal reflux disease.Take medicine of the present invention, treat 3 courses for the treatment of, heartburn, pantothenic acid obviously alleviates, and all the other symptoms also in alleviation trend, continue to take 3 courses for the treatment of, and recovery from illness is followed up a case by regular visits to after half a year without recurrence.
2, ten thousand certain, female, 60 years old, heartburn, pantothenic acid recurrent exerbation more than 8 years.There is the discomforts such as heartburn, pantothenic acid for nearly 8 years in patient, does not cause patient's enough attention, also non-systematic treating repeatedly, and be in from taking local Traditional chinese medicine medicament, effect is undesirable, then my institute's row electronic gastroscopy prompting gastroesophageal reflux disease.Patient is heartburn, pantothenic acid at present, and companion's belch does not relax, and epigastrium distension does not relax, bitter taste, and sense both sides side of body flank distension is uncomfortable.Check: abdomen is soft, and abdominal part is without tenderness and rebound tenderness, and Liver and kidney district is without percussion pain.Diagnosis: gastroesophageal reflux disease.Take medicine of the present invention, every day 1 dose, after 3 courses for the treatment of, heartburn, pantothenic acid alleviates, and swelling disappears, and all the other symptoms alleviate.Continue to take 4 courses for the treatment of, recovery from illness, follow up a case by regular visits to after 1 year without recurrence.
Claims (1)
1. one kind is used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease, it is characterized in that being made up of the crude drug of following weight portion: Radix Bupleuri 5 ~ 9, the Radix Paeoniae Alba 4 ~ 7, Fructus Aurantii 4 ~ 8, Fructus Toosendan 4 ~ 7, Rhizoma Corydalis 4 ~ 8, Rhizoma Coptidis 5 ~ 8, Fructus Evodiae 6 ~ 9, Radix Curcumae 6 ~ 9, Endothelium Corneum Gigeriae Galli 7 ~ 9, Radix Clematidis 6 ~ 9, Radix Notoginseng 2 ~ 5, Pseudobulbus Bletillae (Rhizoma Bletillae) 6 ~ 9, Os Sepiae 2 ~ 5, Bulbus Fritillariae Thunbergii 4 ~ 6, Concha Arcae 2 ~ 4, Concha Ostreae 4 ~ 6, Radix Glycyrrhizae Preparata 2 ~ 4, Concha Margaritifera 7 ~ 9, by medicinal for above-mentioned raw materials water soaking, filtrate of removing slag after decocting to obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510726779.XA CN105213991B (en) | 2015-10-23 | 2015-10-23 | Traditional Chinese medicine composition for treating gastroesophageal reflux disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510726779.XA CN105213991B (en) | 2015-10-23 | 2015-10-23 | Traditional Chinese medicine composition for treating gastroesophageal reflux disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105213991A true CN105213991A (en) | 2016-01-06 |
| CN105213991B CN105213991B (en) | 2020-06-12 |
Family
ID=54983503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510726779.XA Active CN105213991B (en) | 2015-10-23 | 2015-10-23 | Traditional Chinese medicine composition for treating gastroesophageal reflux disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105213991B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113713073A (en) * | 2021-08-26 | 2021-11-30 | 朱伟宁 | Traditional Chinese medicine composition for treating spleen and stomach damp-heat type chronic atrophic gastritis |
| CN114470092A (en) * | 2022-03-10 | 2022-05-13 | 徐英剑 | Pharmaceutical composition for treating upper gastrointestinal hemorrhage and powder thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306941A (en) * | 2014-10-30 | 2015-01-28 | 上海中医药大学附属岳阳中西医结合医院 | Medicament for treating non-erosive gastro-oesophageal reflux disease and application of medicament |
| CN104906554A (en) * | 2015-07-16 | 2015-09-16 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating refractory gastroesophageal reflux disease and application thereof |
-
2015
- 2015-10-23 CN CN201510726779.XA patent/CN105213991B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306941A (en) * | 2014-10-30 | 2015-01-28 | 上海中医药大学附属岳阳中西医结合医院 | Medicament for treating non-erosive gastro-oesophageal reflux disease and application of medicament |
| CN104906554A (en) * | 2015-07-16 | 2015-09-16 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating refractory gastroesophageal reflux disease and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 毕卫珍: "健脾疏肝汤治疗胆汁反流性胃炎60例临床观察", 《山东中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113713073A (en) * | 2021-08-26 | 2021-11-30 | 朱伟宁 | Traditional Chinese medicine composition for treating spleen and stomach damp-heat type chronic atrophic gastritis |
| CN114470092A (en) * | 2022-03-10 | 2022-05-13 | 徐英剑 | Pharmaceutical composition for treating upper gastrointestinal hemorrhage and powder thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105213991B (en) | 2020-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103550529B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis | |
| CN102166284B (en) | Medicine for treating reflux esophagitis and preparation method thereof | |
| CN103301400B (en) | A kind of Chinese medicine composition and preparation method for the treatment of chronic atrophic gastritis | |
| CN101306180B (en) | Gastropathy treating medicine | |
| CN104524227B (en) | A kind of Chinese medicine preparation and preparation method being used for the treatment of dental caries | |
| CN106361993A (en) | Medicinal composition for preventing and treating gastric mucosal lesion and preparation method of medicinal composition | |
| CN102949553B (en) | Traditional Chinese medicine composition for treating superficial gastritis | |
| CN102210818B (en) | Chinese medicine for treating gastrorrhagia | |
| CN105213991A (en) | Be used for the treatment of the Chinese medicine composition of gastroesophageal reflux disease | |
| CN102949695B (en) | Traditional Chinese medicine for treating intractable hiccough | |
| CN102861199A (en) | Traditional Chinese medicine composition for treating gastroesophageal reflux disease and preparation method | |
| CN102698189B (en) | Chinese medicinal composition and preparation with function of treating helicobacter pylori in stomach and preparation method thereof | |
| CN104510980A (en) | Composition used for treating chronic gastritis | |
| CN104547757B (en) | It is a kind of to treat tonsillitis, the Chinese medicine of adenoids | |
| CN103230518B (en) | Traditional Chinese medical composition for treating peptic ulcer | |
| CN105214067A (en) | A kind of medicine for the treatment of cancer patients diarrhoea | |
| CN103830481A (en) | Medicine for treating recurrent respiratory tract infection of children | |
| CN102961662B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN103816327B (en) | One treats ileac Chinese medicine composition and preparation method thereof | |
| CN103893732B (en) | A kind of Tibetan medicine treating chronic gastritis | |
| CN103638410B (en) | A kind of Orally-administered decoction for the treatment of periodontitis | |
| CN113230379B (en) | Qi-regulating and lump-relieving decoction for treating gastroparesis syndrome after abdominal tumor surgery | |
| CN103893337B (en) | A kind of external traditional Chinese medicinal application for the treatment of cesarean postoperate intestinal function recovery | |
| CN103372185B (en) | The medicine for the treatment of chronic bronchitis | |
| CN104491504A (en) | Traditional Chinese medicine preparation for treating pleural effusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |